- Home
- SAFE vs ADPT Comparison
SAFE vs ADPT Comparison
Compare SAFE & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFE
- ADPT
- Stock Information
- Founded
- SAFE 2016
- ADPT 2009
- Country
- SAFE United States
- ADPT United States
- Employees
- SAFE N/A
- ADPT N/A
- Industry
- SAFE Real Estate Investment Trusts
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAFE Real Estate
- ADPT Health Care
- Exchange
- SAFE Nasdaq
- ADPT Nasdaq
- Market Cap
- SAFE 1.3B
- ADPT 1.1B
- IPO Year
- SAFE 2017
- ADPT 2019
- Fundamental
- Price
- SAFE $18.29
- ADPT $7.52
- Analyst Decision
- SAFE Buy
- ADPT Strong Buy
- Analyst Count
- SAFE 9
- ADPT 5
- Target Price
- SAFE $25.33
- ADPT $9.40
- AVG Volume (30 Days)
- SAFE 389.7K
- ADPT 2.2M
- Earning Date
- SAFE 05-05-2025
- ADPT 05-06-2025
- Dividend Yield
- SAFE 3.89%
- ADPT N/A
- EPS Growth
- SAFE N/A
- ADPT N/A
- EPS
- SAFE 1.48
- ADPT N/A
- Revenue
- SAFE $388,662,000.00
- ADPT $178,957,000.00
- Revenue This Year
- SAFE N/A
- ADPT $21.21
- Revenue Next Year
- SAFE $7.44
- ADPT $21.98
- P/E Ratio
- SAFE $12.29
- ADPT N/A
- Revenue Growth
- SAFE 7.48
- ADPT 5.10
- 52 Week Low
- SAFE $15.55
- ADPT $2.28
- 52 Week High
- SAFE $28.80
- ADPT $9.01
- Technical
- Relative Strength Index (RSI)
- SAFE 50.11
- ADPT 45.59
- Support Level
- SAFE $17.75
- ADPT $7.11
- Resistance Level
- SAFE $18.50
- ADPT $9.01
- Average True Range (ATR)
- SAFE 0.54
- ADPT 0.57
- MACD
- SAFE -0.08
- ADPT -0.03
- Stochastic Oscillator
- SAFE 37.20
- ADPT 28.88
About SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).